The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed Is BPC 157 Banned? Oral vs. Injectable Forms Explained They Call It the 'Wolverine Peptide.' And Everyone from Biohackers to Your Dad Wants It Now.